Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity

Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity

US Patent 6191102 · Granted Feb 20, 2001

Estimated economic value: $393,022,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Co-agonists at GLP-1 and GIP receptors suitable for oral delivery2023
GIP derivatives and uses thereof2023
FGF21 C-terminal peptide optimization2022
Glucagon/GLP-1 receptor co-agonists2020
Insulin-incretin conjugates2020
Aqueously soluble and chemically stable glucagon peptides2020
GIP derivatives and uses thereof2020
Lipidated amide-based insulin prodrugs2019
Incretin-insulin conjugates2019
Single chain insulin agonists exhibiting high activity at the insulin receptor2019
Glucagon/GLP-1 receptor co-agonists2019
Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypep2018